Imprimis Pharmaceuticals and SightLife Surgical Sign Agreement for National Launch of Serum Tears™ Imprimis begins roll-out of dry eye disease formulary with innovative autologous serum eye drop programImprimis Pharmaceuticals, Inc. • May 2nd, 2017 • Pharmaceutical preparations
San Diego, Calif. and Seattle, Wash. – May 2, 2017 – Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) (“Imprimis”), an ophthalmology-focused pharmaceutical company, and SightLife Surgical (“SightLife Surgical”), a cornea-focused organization providing comprehensive services to ophthalmic surgeons, announced the signing of an exclusive strategic sales and marketing agreement. Under the agreement, SightLife Surgical will deploy their sales team to offer Imprimis’ Serum Tears™ compounded formulations to physicians, large practice groups, surgery centers, hospitals and healthcare organizations nationwide. Imprimis’ Serum Tears™ autologous serum eye drops (ASEDs) are prescribed for chronic dry eye patients who do not respond to traditional dry eye treatments.
STRATEGIC SALES & MARKETING AGREEMENTMarketing Agreement • May 2nd, 2017 • Imprimis Pharmaceuticals, Inc. • Pharmaceutical preparations • California
THIS STRATEGIC SALES & MARKETING AGREEMENT (the “Agreement”) is effective as of the last date provided for on the signature page and is entered into by and between SightLife Surgical, Inc., a Delaware corporation, having its principal place of business at 1200 6th Ave, Ste. 300, Seattle, WA 98101 (“Surgical”) and Imprimis Pharmaceuticals, Inc., a Delaware corporation, and its subsidiaries, having its principal place of business at 12264 El Camino Real, Suite 350, San Diego, CA 92130 (“Imprimis”).
